• Home
  • »
  • Newsroom
  • »
  • Researchers to Present Data on Soliris® (eculizumab) as a Treatment f...

Researchers to Present Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS at ASN 2014 Annual Meeting

Thursday, October 23, 2014 4:15 pm EDT

Dateline:

CHESHIRE, Conn.

Public Company Information:

NASDAQ:
ALXN
"Characteristics of 406 Adult and Pediatric Patients in the Global aHUS Registry"

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers will present seven posters detailing findings from clinical studies of Soliris® (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS) as well as from the Global aHUS Registry at the annual meeting of the American Society of Nephrology (ASN), being held November 11-16, 2014, in Philadelphia. aHUS is a genetic, chronic, ultra-rare disease associated with vital organ failure and premature death. Abstracts summarizing these presentations, which enhance the understanding of aHUS to provide optimal care for patients, were published on the ASN website and can be accessed using the links below.

Soliris, a first-in-class terminal complement inhibitor, is approved in nearly 40 countries as a treatment for patients with aHUS and in nearly 50 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare and life-threatening blood disorder characterized by complement-mediated hemolysis (destruction of red blood cells). Both aHUS and PNH are caused by chronic uncontrolled complement activation.

The following abstracts will be presented in a poster session on Saturday, November 15, 2014, from 10:00 a.m. to 12:00 p.m., Eastern Standard Time (EST):

Abstract 783: “Eculizumab Inhibits Thrombotic Microangiopathy and Improves Renal Function in Adult Atypical Hemolytic Uremic Syndrome Patients: 1-Year Update,” Fakhouri, et al.

Accessible at: http://www.abstracts2view.com/asn_2014/view.php?nu=783&type=abstract

Abstract 1667: “Characteristics of 406 Adult and Pediatric Patients in the Global aHUS Registry,” Licht, et al.

Accessible at: http://www.abstracts2view.com/asn_2014/view.php?nu=1667&type=abstract

Abstract 1952: “Time to End-Stage Renal Disease in Patients With Atypical Hemolytic Uremic Syndrome Receiving Supportive Care and Eculizumab,” Khursigara, et al.

Accessible at: http://www.abstracts2view.com/asn_2014/view.php?nu=1952&type=abstract

Abstract 2703: “Eculizumab Reduces Terminal Complement, Complement Alternative Pathway Activation, Inflammation, Endothelial Damage, Thrombosis and Renal Injury Markers in Patients With Atypical Hemolytic Uremic Syndrome,” Cofiell, et al.

Accessible at: http://www.abstracts2view.com/asn_2014/view.php?nu=2703&type=abstract

Abstract 1915: “Safety and Efficacy of Eculizumab in Pediatric Patients With aHUS, With or Without Baseline Dialysis,” Vande Walle, et al.

Accessible at: http://www.abstracts2view.com/asn_2014/view.php?nu=1915&type=abstract

Abstract 2728: “Safety and Efficacy of Eculizumab in Adult aHUS Patients, With or Without a History of Renal Transplant,” Loirat, et al.

Accessible at: http://www.abstracts2view.com/asn_2014/view.php?nu=2728&type=abstract

Abstract 2726: “Eculizumab Safety and Efficacy in Adult Patients With aHUS, With or Without Baseline Dialysis,” Fakhouri, et al.

Accessible at: http://www.abstracts2view.com/asn_2014/view.php?nu=2726&type=abstract

About Soliris® (eculizumab)

Soliris is a first-in-class terminal complement inhibitor developed from the laboratory through regulatory approval and commercialization by Alexion. Soliris is approved in the U.S. (2007), European Union (2007), Japan (2010) and other countries as the first and only treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare and life-threatening blood disorder, characterized by complement-mediated hemolysis (destruction of red blood cells). Soliris is indicated to reduce hemolysis. Soliris is also approved in the U.S. (2011), the European Union (2011), Japan (2013) and other countries as the first and only treatment for patients with atypical hemolytic uremic syndrome (aHUS), a debilitating, ultra-rare and life-threatening genetic disorder characterized by complement-mediated thrombotic microangiopathy, or TMA (blood clots in small vessels). Soliris is indicated to inhibit complement-mediated TMA. The effectiveness of Soliris in aHUS is based on its effects on TMA and renal function. Soliris is not indicated for the treatment of patients with Shiga-toxin E. coli-related hemolytic uremic syndrome (STEC-HUS). For the breakthrough medical innovation in complement inhibition, Alexion and Soliris have received some of the pharmaceutical industry's highest honors: the Prix Galien USA (2008, Best Biotechnology Product) and France (2009, Rare Disease Treatment).

More information including the full U.S. prescribing information on Soliris is available at www.soliris.net.

Important Safety Information

The U.S. product label for Soliris includes a boxed warning: "Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early [see Warnings and Precautions (5.1)]. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies. Immunize patients with a meningococcal vaccine at least two weeks prior to administering the first dose of Soliris, unless the risks of delaying Soliris therapy outweigh the risk of developing a meningococcal infection. [See Warnings and Precautions (5.1) for additional guidance on the management of the risk of meningococcal infection]. Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected. Soliris is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the Soliris REMS, prescribers must enroll in the program [see Warnings and Precautions (5.2)]. Enrollment in the Soliris REMS program and additional information are available by telephone: 1-888-SOLIRIS (1-888-765-4747)."

In patients with PNH, the most frequently reported adverse events observed with Soliris treatment in clinical studies were headache, nasopharyngitis (runny nose), back pain and nausea. Soliris treatment of patients with PNH should not alter anticoagulant management because the effect of withdrawal of anticoagulant therapy during Soliris treatment has not been established. In patients with aHUS, the most frequently reported adverse events observed with Soliris treatment in clinical studies were headache, diarrhea, hypertension, upper respiratory infection, abdominal pain, vomiting, nasopharyngitis, anemia, cough, peripheral edema, nausea, urinary tract infections, pyrexia. Soliris is not indicated for the treatment of patients with Shiga-toxin E. coli-related hemolytic uremic syndrome (STEC-HUS). Please see full prescribing information for Soliris, including BOXED WARNING regarding risk of serious meningococcal infection.

About Alexion

Alexion is a biopharmaceutical company focused on serving patients with severe and rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition and has developed and markets Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. Soliris is currently approved in nearly 50 countries for the treatment of PNH and in nearly 40 countries for the treatment of aHUS. Alexion is evaluating other potential indications for Soliris in additional severe and ultra-rare disorders beyond PNH and aHUS, and is developing other highly innovative biotechnology product candidates, including asfotase alfa, across multiple therapeutic areas. This press release and further information about Alexion can be found at: www.alexionpharma.com.

[ALXN-G]

Contact:

Alexion:
Media
Irving Adler, 203-271-8210
Executive Director, Corporate Communications
or
Kim Diamond, 203-439-9600
Senior Director, Corporate Communications
or
Investors
Elena Ridloff, 203-699-7722
Executive Director, Investor Relations